Kailera Therapeutics (NASDAQ:KLRA) Trading 9.8% Higher – Still a Buy?

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) rose 9.8% during trading on Wednesday . The stock traded as high as $20.37 and last traded at $20.36. Approximately 219,072 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 610,344 shares. The stock had previously closed at $18.55.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. TD Cowen initiated coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price target on the stock. Evercore started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating for the company. William Blair started coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating on the stock. Zacks Research raised shares of Kailera Therapeutics to a “hold” rating in a research note on Wednesday, May 13th. Finally, JPMorgan Chase & Co. began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $42.75.

Kailera Therapeutics Price Performance

The firm has a 50-day moving average of $21.89.

Insiders Place Their Bets

In other news, major shareholder Rtw Investments, Lp bought 500,000 shares of Kailera Therapeutics stock in a transaction dated Monday, April 20th. The shares were bought at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the purchase, the insider owned 10,776,820 shares of the company’s stock, valued at approximately $172,429,120. This trade represents a 4.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Adam Koppel bought 1,562,500 shares of the stock in a transaction dated Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $25,000,000.00. Following the acquisition, the director owned 22,583,268 shares in the company, valued at $361,332,288. The trade was a 7.43% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 10,460,938 shares of company stock worth $167,375,008 over the last three months.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.